Charles Schwab’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,239,555
| Closed | -$5.08M | – | 3720 |
|
|
2022
Q1 | $5.08M | Buy |
1,239,555
+45,805
| +4% | +$166K | ﹤0.01% | 2273 |
|
|
2021
Q4 | $4.26M | Buy |
1,193,750
+32,378
| +3% | +$113K | ﹤0.01% | 2430 |
|
|
2021
Q3 | $4.23M | Buy |
1,161,372
+53,498
| +5% | +$216K | ﹤0.01% | 2454 |
|
|
2021
Q2 | $4.83M | Buy |
1,107,874
+17,435
| +2% | +$71K | ﹤0.01% | 2371 |
|
|
2021
Q1 | $4.48M | Buy |
1,090,439
+62,183
| +6% | +$269K | ﹤0.01% | 2351 |
|
|
2020
Q4 | $4.1M | Buy |
1,028,256
+3,276
| +0.3% | +$10.6K | ﹤0.01% | 2315 |
|
|
2020
Q3 | $2.77M | Sell |
1,024,980
-34,910
| -3% | -$96.6K | ﹤0.01% | 2375 |
|
|
2020
Q2 | $2.92M | Buy |
1,059,890
+93,426
| +10% | +$261K | ﹤0.01% | 2283 |
|
|
2020
Q1 | $2.28M | Buy |
966,464
+18,360
| +2% | +$62.4K | ﹤0.01% | 2224 |
|
|
2019
Q4 | $4.46M | Buy |
948,104
+1,926
| +0.2% | +$7.88K | ﹤0.01% | 2079 |
|
|
2019
Q3 | $3.17M | Buy |
946,178
+21,024
| +2% | +$69.2K | ﹤0.01% | 2204 |
|
|
2019
Q2 | $3.04M | Buy |
925,154
+68,438
| +8% | +$198K | ﹤0.01% | 2201 |
|
|
2019
Q1 | $2.6M | Buy |
856,716
+36,191
| +4% | +$117K | ﹤0.01% | 2274 |
|
|
2018
Q4 | $2.23M | Sell |
820,525
-8,261
| -1% | -$27.2K | ﹤0.01% | 2296 |
|
|
2018
Q3 | $2.79M | Buy |
828,786
+84,598
| +11% | +$261K | ﹤0.01% | 2319 |
|
|
2018
Q2 | $1.92M | Buy |
744,188
+32,626
| +5% | +$81.2K | ﹤0.01% | 2392 |
|
|
2018
Q1 | $1.57M | Buy |
711,562
+104,733
| +17% | +$236K | ﹤0.01% | 2404 |
|
|
2017
Q4 | $1.21M | Buy |
606,829
+45,893
| +8% | +$99.9K | ﹤0.01% | 2459 |
|
|
2017
Q3 | $1.82M | Buy |
560,936
+27,360
| +5% | +$84.4K | ﹤0.01% | 2326 |
|
|
2017
Q2 | $1.72M | Buy |
533,576
+244,483
| +85% | +$693K | ﹤0.01% | 2270 |
|
|
2017
Q1 | $822K | Buy |
289,093
+26,847
| +10% | +$64.6K | ﹤0.01% | 2489 |
|
|
2016
Q4 | $612K | Buy |
262,246
+24,178
| +10% | +$46K | ﹤0.01% | 2587 |
|
|
2016
Q3 | $400K | Buy |
238,068
+20,470
| +9% | +$25.1K | ﹤0.01% | 2698 |
|
|
2016
Q2 | $229K | Sell |
217,598
-249,999
| -53% | -$242K | ﹤0.01% | 2884 |
|
|
2016
Q1 | $407K | Buy |
467,597
+7,650
| +2% | +$7.4K | ﹤0.01% | 2658 |
|
|
2015
Q4 | $557K | Buy |
459,947
+9,750
| +2% | +$13.6K | ﹤0.01% | 2608 |
|
|
2015
Q3 | $766K | Buy |
450,197
+25,635
| +6% | +$50.3K | ﹤0.01% | 2469 |
|
|
2015
Q2 | $884K | Buy |
424,562
+106,669
| +34% | +$259K | ﹤0.01% | 2468 |
|
|
2015
Q1 | $862K | Buy |
317,893
+15,660
| +5% | +$39.7K | ﹤0.01% | 2425 |
|
|
2014
Q4 | $777K | Buy |
302,233
+42,171
| +16% | +$94.7K | ﹤0.01% | 2458 |
|
|
2014
Q3 | $476K | Buy |
260,062
+4,417
| +2% | +$9.63K | ﹤0.01% | 2610 |
|
|
2014
Q2 | $683K | Sell |
255,645
-34,529
| -12% | -$104K | ﹤0.01% | 2503 |
|
|
2014
Q1 | $1.02M | Buy |
290,174
+36,355
| +14% | +$161K | ﹤0.01% | 2282 |
|
|
2013
Q4 | $1.14M | Sell |
253,819
-13,435
| -5% | -$54.7K | ﹤0.01% | 2208 |
|
|
2013
Q3 | $1.17M | Buy |
267,254
+3,445
| +1% | +$15K | ﹤0.01% | 2146 |
|
|
2013
Q2 | $1.12M | Buy |
+263,809
| New | +$1.02M | ﹤0.01% | 2099 |
|
Other funds holding ATRS
Charles Schwab's ATRS Position: Q2 2022 in Review
Charles Schwab sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 1,239,555 shares — an estimated $5.08M sold.
Charles Schwab first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $5.08M in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Charles Schwab reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Charles Schwab sold 1,239,555 Antares Pharma, Inc. shares in Q2 2022, an estimated $5.08M.
- Charles Schwab first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- Charles Schwab's Antares Pharma, Inc. position peaked at $5.08M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.